CA-XPRIZE
3.10.2020 03:10:11 CEST | Business Wire | Press release
XPRIZE today announced that the million dollar Next-Gen Mask Challenge received record-breaking team entry numbers in their newest initiative that called upon young innovators from around the world ages 15 to 24 to reimagine protective face masks. By limiting participation to youth participants, XPRIZE aimed to galvanize the next generation of innovators, and the overwhelming response demonstrated the eagerness of Gen-Z creators to make an impact on the world.
Within 60 days, the XPRIZE Next-Gen Mask Challenge received 992 interested participants, making it the largest, most prolific call-to-action in XPRIZE Foundation history. Potential teams originated from 76 countries, proof of the global desire to overcome many of the common barriers associated with traditional protective masks.
“We understand that masks can be ill-fitting, uncomfortable, unfashionable, and that the most effective masks are often unavailable or expensive for everyday people. We need an alternative, that’s why XPRIZE is turning to the world’s young innovators to help reinvent the face mask and create an accessible alternative that will help protect against the spread of COVID-19,” said Peter H. Diamandis, XPRIZE founder and executive chairman. “We’re going to take the top 25 designs and find out if they’re manufacturable. Once we determine their manufacturability, we’re going to take the top 10 of those and go out to influencers to gauge acceptance.”
XPRIZE, a nonprofit organization that uses global competitions to crowdsource solutions to some of the world’s biggest challenges, recognized that currently one-third of the US population doesn’t regularly wear a mask, despite evidence showing that when used properly they can significantly reduce transmission of viruses. The $1M XPRIZE Next-Gen Mask Challenge contest, sponsored by Marc Benioff and Jim Cramer, will award the grand prize to young innovators whose mask design best combines ingenuity, effectiveness, X-factor of style, and ability to overcome common barriers to use as measured by a pre-Challenge poll taken by over 3,000 participants.
“There is a gigantic amount of evidence that masks can stop the spread,” said Jim Cramer, the host of Mad Money on CNBC. “I’m so proud to sponsor the XPRIZE Next-Gen Mask Challenge with Marc Benioff, it's amazing how resourceful people are when you ask them to design a mask that those who object to most masks might even wear.”
“If everyone in the United States wore a mask for 3 weeks — just 3 weeks — we would not have anymore coronavirus, because there would be no more spread, but people do not want to wear masks,” said sponsor Marc Benioff.
XPRIZE’s Next-Gen Mask Challenge will culminate in a final judging event, with in-lab testing this October supported by partners 3M and Honeywell and winners will be announced later this year. Additional details and the list of teams moving forward can be found here.
ABOUT XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, XPRIZE NextGen Mask Challenge and $5 Million XPRIZE Rapid COVID Testing. For more information, visit xprize.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
